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Continuous positive airway pressure (CPAP) is the most widely used therapy for obstructive sleep apnoea (OSA). 
Despite its general efficacy, oxygen desaturation due to hypoventilation persists in some patients. The present study 
analysed the factors which are associated with this primary failure and, moreover, examined the effect of a bilevel 
positive airway pressure (BiPAP) trial. 
In a 15-month period, 13 patients with OSA (Group A) failed to respond to initial CPAP therapy defined by a 
remaining apnoea/hypoproea index (AHI) of 2 5 or a mean noctural SaO, ~90%. These patients were compared to 
an age- and AHI-matched control group (Group B) successfully treated by CPAP. A logistic regression analysis was 
performed to identify factors which are associated with initial failure to CPAP. Patients of the CPAP-failure group 
were treated with nasal BiPAP in the control mode. 
These patients were significantly more obese than patients of the control group (mean body mass index 44.2 & 7.7 
vs 31.2 f 6.3 kg m- 2; P<O.OOl). PaO, at rest (P<O.OOl) and at exercise (P<O.O05) was significantly lower in Group 
A patients. PaCO, at rest (P<O.OOl) was significantly higher in Group A patients and changed for the worse during 
exercise, whereas it improved in the control group. Group A patients spent significantly (P<O.OOOl) more time with 
oxygen saturation ~90%. The percentage of time spent at ~90% of SaO, was the only factor which was 
independently associated with the initial failure of CPAP (OR 1.13; 95% Cl 1.0-1.2). After 3 months of treatment 
with BiPAP, the patients’ blood gas values while awake improved significantly (PcO.05) for PaO, as well as for 
PaCO,. 
In conclusion, patients with OSA resistant to initial CPAP are morbidly obese with impaired awake blood gas 
values. The percentage of time spent at <90% of nocturall SaO, is independently associated with initial failure of 
CPAP. BiPAP in the control mode is adequate for noctural ventilation, and improves awake blood gas values. 
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Introduction 
Nocturnal ventilation with nasal continuous positive 
airway pressure (CPAP) is generally accepted as the treat- 
ment of choice in obstructive sleep apnoea/hypopnoea 
syndrome (OSA) (1). It abolishes rapidly obstructive 
apnoea and hypopnoea (2) by increasing the pressure in the 
pharyngeal airway, thus reversing the transmural pressure 
gradient across the pharyngeal airway (3). It is based on the 
pathophysiology of the disease and therefore acts as a 
pneumatic splint. Besides these direct effects of CPAP on 
respiration, fragmentation of sleep is reduced, which results 
in an improvement in daytime sleepiness and cognitive 
performance (4). It is therefore concluded that long-term 
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compliance is, in part, the result of a careful initiation 
of this therapy and the subsequent reversal of sleep 
fragmentation (5). 
The level of pressure required to eliminate apnoea, 
hypopnoea and snoring must be individually determined in 
ranges from low to high. Even if silent flow limitation is 
eliminated, a subgroup of patients continue to have marked 
oxygen desaturation mainly due to hypoventilation and 
subsequently exhibit nocturnal CO, retention (6). The 
therapeutic efficacy and the incidence of side-effects of 
CPAP therapy was investigated in a large series of 1140 
patients with obstructive sleep apnoea representing all 
degrees of severity from obstructive snoring with arousals 
to the Pickwickian syndrome (7). The apnoealhypopnoea 
index (AHI) could not be lowered under 10 in 5.5% of the 
whole group, partly because of central apnoea or hypo- 
ventilation (7). Up to now, it was not clear why some 
patients exhibit hypoventilation despite CPAP and 
which factors are associated with the initial failure of 
CPAP. These patients were considered to have a reduced 
ventilatory drive and have daytime hypercapnia (8). 
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TABLE 1. Anthropometric data of patients who failed to respond to continuous positive airway 
pressure (CPAP) (Group A) and patients of the control group (Group B) 
Parameter 
Group A 
(CPAP failure) Significance 
Group B 
(Control) 
Age (years) 57 (41-61) n.s. 56 (41-66) 
Sex 9M; 4F n.s. 9M; 4F 
BMI (kg m - *) 44.4 (31.5-56.3) P<O.OOl 30.8 (22.041.0) 
Dyspnoea (%) 92.3 P<O.OOl 23.0 
Daytime sleepiness (D/o) 100 n.s. 100 
Nocturnal snoring (%) 100 n.s. 100 
Pulmonary hypertension (%) 23.0 n.s. 0 
BMI, body-mass index; n.s., not significant. 
Consequently, nasal intermittent positive pressure ventila- 
tion (NIPPV) was performed as a short-term intervention, 
before switching back to CPAP therapy (8). 
The purpose of the present study was to analyse the 
factors which are associated with a primary failure in the 
intial CPAP therapy in order to identify these patients 
before starting CPAP therapy. Therefore, patients with 
OSA who resisted refractory to initial CPAP therapy were 
compared with an age- and AHI-matched control group of 
patients who responded to CPAP therapy. Furthermore, 
the former were tested with intermittent positive pressure 
ventilation by pressure preset ventilators in the controlled 
mode (bilevel), and this paper reports on the authors’ 
experience with this mode of ventilation over a 3-month 
period. 
Methods 
Nasal CPAP therapy was initiated in 146 patients with OSA 
that was confirmed by polysomnography over a 15-month 
period. <Thirteen patients (Group A) failed to respond to 
CPAP, i.e. defined as a remaining AH1 of 25 or a mean 
oxygen saturation of ~90% due to hypoventilation. 
Anthropometric data, lung-function test, blood gases at rest 
and at exercise before starting ventilation therapy, and 
polysomnographic data were compared to an age- and 
AHI-matched control group successfully treated by CPAP 
(Group B). Age was the primary match criteria and AH1 
the secondary one. Patients with central sleep apnoea or 
obstructive lung disease (FEV,/ VC ~60%) were excluded in 
both groups. 
Standard polysomnography was performed in the 
sleep laboratory. Two leads of electroencephalogram 
(C,A,; C,A,), two leads of electro-oculogram, a submental 
electromyogram, an anterior tibia1 electromyogram and an 
electrocardiogram were continuously registered by surface 
electrodes. Respiration was also recorded continuously: 
oro-nasal airflow, abdominal and chest wall movements 
by inductive-plethysmography and transcutaneous oxygen 
saturation by finger oxymeter. Snoring sounds were 
recorded by larynx microphone. In addition, mask 
pressures were recorded in cases of nasal ventilation. 
All variables were recorded by a computerized system 
(NewMedics, ohringen, Germany). Sleep was staged manu- 
ally according to standard criteria of Rechtschaffen and 
Kales (9). Apnoea was defined as a cessation of airflow for 
more than 10 s regardless of oxygen saturation, and it was 
classified as obstructive, central or mixed in the presence or 
absence of continued respiratory efforts. Hypopnoea was 
defined as a reduction in airflow of at least 50% followed 
either by an oxygen desaturation of at least 4 percentage 
points or an arousal. The total number of apnoea and 
hypopnoea divided by total sleep time make up the apnoea 
index (AI) and the hypopnoea index (HI). The sum of AI 
and HI then became the apnoealhypopnoea index (AHI), 
which established the diagnosis of obstructive sleep apnoea 
at 210. 
Standard lung function tests and arterial blood gas 
tensions at rest were measured in the sitting position. 
Arterial blood gas tensions at exercise were also measured 
in the sitting position on a cycle ergometer with a work load 
of 50 W in a 6-min interval. Mouth occlusion pressure 
measurements were obtained as follows (10): a magnetic 
valve in front of the pneumotachograph was completely 
occluded with the onset of inspiration and reopened auto- 
matically after 120 ms (PO.l). In the same way, PO.1 max 
was determined during maximal voluntary inspiratory 
effort. Since PO. 1 reflects actual inspiratory pressure genera- 
tion and PO.1 max is representative of maximal inspiratory 
pressure generation, the PO. l/PO. 1 max ratio is an adequate 
index for assessing the relative force of the inspiratory 
muscles (10). In order to assess a functional stenosis of the 
trachea, roentgenograms of the trachea were obtained 
during Valsalva and Mueller manoeuvre. Pulmonary artery 
pressure (Pap) measurements were performed noninvasively 
by Doppler echocardiography (pulmonary hypertension 
defined by systolic PAP 2 30 mmHg). Daytime sleepiness 
and dyspnoea were graded by visual analogue scales. 
Patients were instructed to use the CPAP device 
(Weinmann, Hamburg, Germany) at a low pressure during 
the daytime to get acquainted with the system. Nasal CPAP 
therapy was started in the second sleep study night. The 
mask pressure was set at 5 cm H,O at the beginning and 
raised by 1 cm H,O increments until apnoeas, hypopnoeas 
and snoring were abolished. Hypoventilation was defined as 
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TABLE 2. Data of lung function, blood gas values, baseline polysomnography and continuous 
positive airway pressure (CPAP) polysomnography 
Parameter 
Group A 
(CPAP failure) Significance 
Group B 
(Control) 
AaDO, 
PaO, rest 
PaO, exercise 
PaCO, rest 
PaCO, exercise 
FEV, 
FEV, predicted 
FEVJVC ratio 
Baseline polysomnography 
AI 
HI 
AH1 
Mean SaO, 
Minimal SaO, 
SaO,<90% 
CPAP polysomnography 
AH1 
Mean SaO, 
CPAP pressure (cmH,O) 
@Pa) 
bmHg1 
&Pa) 
[~Hizl 
VW 
bmfkl 
&Pa) 
bW4 
@Pa) 
[mm&l 
6) 
(“W 
WI 
(%I 
(%I 
(%) 
(W 
4.5 (2.5-6.0) 
[34.0 (1945)] 
7.78 (4.84-8.98) 
[58.5 (36467.5)] 
9.14 (5.73-8.98) 
[68.7 (43.1-67.5)] 
5.95 (4.85-9.92) 
[44.7 (36.5-74.6)] 
6.29 (4.73-9.64) 
[47.3 (35+72.5)] 
2.0 (1.3-3.3) 
61.2 (48.0-99.4) 
80.5 (68.5-90.0) 
16.6 (11.1-123.3) 
14.2 (1.945.4) 
44.4 (13.9-126.7) 
86 (75-91) 
63 (38-81) 
82 (14-100) 
14.3 (5.0-29.3) 
89 (8494) 
12.5 (12-14) 
n.s. 
P<O.OOl 
P<O.O05 
P<O.OOl 
P<O.O05 
ns. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
P<0~0001 
PCO.05 
P<0~0001 
4.1 (2.9-5.5) 
[31.0 (22-41)] 
9.48 (7.22-l 1.0) 
[71.3 (54.3-82.9)] 
11.49 (9.02-12.53) 
[86.4 (67.8-94.2)] 
5.09 (4.47-5.64) 
[38.3 (33.642.4)] 
4.91 (4.60-5.47) 
[36.9 (34.641.1)] 
2.5 (1.74.0) 
77.7 (52.9-102.6) 
73.1 (61.2-94%0) 
23.0 (18.0-62.2) 
6.4 (O-64.0) 
38.0 (18.0-73.0) 
92 (89-95) 
79 (40-88) 
15 (l-35) 
0.5 ((K2.8) 
95 (91-99) 
8.0 (5-10) 
n.s., not significant. See text for abbreviations. 
an oxygen desaturation of 24% and a reduction in airflow 
of at least 50% despite an accurate pressure signal and 
without snoring sounds. Failure of CPAP was considered 
if apnoeas of hypopnoeas persisted despite high pressure 
(2 12 cm H,O) and resulted in a remaining AH1 2 5 or if 
mean oxygen saturation was ~90%. In these cases, a 
pressure preset ventilator (Primedic BIVENT A/C@) with 
an independently adjusted inspiratory pressure (IPAP 
20 cm H,O) and expiratory pressure (EPAP 3 cmH,O) was 
used in the next sleep study. This ventilator was set in the 
control mode with respiratory rates between 16 and 20 
breaths per min and a ratio of 40/60 (inspiratory/expiratory 
time). In one case, a ventilatory assist device (BiPAP@, 
Respironics) with an independently adjusted inspiratory 
and expiratory pressure was used in the spontaneous mode, 
because the patient could not tolerate the control mode. 
Polysomnography and blood gas status measurements were 
repeated in a 3-month follow-up period. 
Differences in continuous variables were assessed using 
non-parametric methods. Comparisons of parameters of 
Groups A and B were performed by Mann-Whitney test 
and descriptions are given by medians (range). Com- 
parisons of parameters according to the response to bilevel 
treatment of Group A were performed by Wilcoxon test, 
and descriptions are given in means & SD. The Chi-squared 
test was used for categorical variables and Fisher’s exact 
test in the case of small expected frequencies. A logistic 
regression analysis using a multivariate forward stepwise 
selection model was performed to assess factors associated 
with failure in CPAP therapy. This model included those 
factors which were significantly different in both groups in 
an univariate analysis. The following factors were tested 
in the univariate analysis: age, body-mass index (BMI), 
FEV,, FEV, predicted, FEV,NC, AaDO,, PaO, rest, 
PaO, exercise, PaCO, rest, PaCO, exercise, PO. 1, PO. 1 max, 
PO.UPO.1 max ratio, haematocrit, haemoglobin, red blood 
cell count, AI, HI, AHI, mean nocturnal SaO, and minimal 
nocturnal SaO,;percentage of time spent at <90% of SaO,. 
In all cases, P values of ~0.05 were considered to be 
significant. Statistical analysis was performed with the 
Statistical Package for the Social Sciences (SPSS) for 
windows@. 
Results 
STUDY POPULATION 
Failure in CPAP therapy occurred in 13 patients (8.9%) out 
of a total of 146 patients over a 15-month period. This 
failure was due to a remaining AH1 of 25 in all cases and 
due to a mean oxygen saturation of ~90% in seven cases 
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FIG. 1. Blood gas values at rest and at exercise of 
patients who failed to respond to continuous positive 
airway pressure (CPAP). 
(54%) despite CPAP with high pressure (2 12 cm H,O). 
These patients (Group A) were significantly (WO.001) 
more obese than the control group that had been success- 
fully treated with CPAP (Group B). Anthropometric data 
of both groups are listed in Table 1. 
Non-responders of CPAP complained significantly more 
about dyspnoea than responders, had significantly worse 
blood gas values at rest and exhibited respiratory type II 
failure during exercise (Table 2). Moreover, PaCO, at rest 
changed for the worse during exercise, revealing a disorder 
in ventilation (Fig. l), whereas it improved in the control 
group (Fig. 2). Spirometric parameters were the same in 
both groups. Data of blood gas analysis and lung function 
are given in Table 2. Mouth occlusion pressures were 
significantly different according to PO.1 (Group A: 
0.31 kPa, Group B: 0.18 kPa; WO.001) and PO.UPO.1 max 
ratio (Group A: 22.5% Group B: 8.3%; P<O.OOl). The PO.1 
max was not significantly different in either group (1.85 kPa 
vs 2.16 kPa). No functional stenosis was found in the 
roentgenograms‘of the trachea. 
POLYSOMNOGRAPHY 
All patients had moderate or severe obstructive apnoeal 
hypopnoea syndrome with no significant differences in 
apnoea or hypopnoea index between the groups (Table 2). 
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FIG. 2. Blood gas values at rest and at exercise of 
patients of the control group. 
Furthermore, no significant differences were found ‘in the 
classification of apnoeas [median obstructive apnoea Group 
A: 58 (20-602); Group B: 113 (10-331); median mixed 
apnoea Group A: 5 (O-164); Group B: 8 (O-110)]. The 
amount of central apnoeas in both groups was less than 
10% of total apnoeas (2 vs 6). Patients in Group A had 
significantly lower mean and minimal nocturnal oxygen 
saturation than patients in Group B, and spent significantly 
more time with an oxygen saturation lower than 90% 
(Table 2). Even when CPAP was administered, the mean 
and minimal noctural oxygen saturation was significantly 
different between the groups, although CPAP pressure was 
significantly higher in Group A patients (Table 2). Most of 
the breathing disorders which occurred under CPAP were 
phases of hypoventilation without perceptible upper airway 
obstruction, and were classified as hypopnoea. 
PREDICTIVE FACTORS FOR FAILURE OF CPAP 
THERAPY 
The following factors were significantly associated with the 
primary failure of CPAP therapy in univariate analysis: 
BMI, mean PaO, at rest and at exercise, mean PaCO, 
at rest and at exercise, mean nocturnal SaO, and the 
percentage of time spent at ~90% of SaO,. In the multi- 
variate analysis, the only factor which was independently 
associated with the initial failure of CPAP therapy was the 
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TABLE 3. Factors associated with initial failure of continuous positive airway pressure (CPAP) 
therapy in univariate and multivariate analysis 
Factor Significance Odds ratio 95% CI 
Univariate analysis 
BMI (kg m-‘) 
Mean PaO, rest (kPa) 
Mean PaO, exercise (kPa) 
Mean PaCO, rest (kPa) 
Mean PaCO, exercise (kPa) 
Mean nocturnal SaO, (%) 
Nocturnal SaO,<90% (%) 
Multivariate analysis 
Nocturnal SaO,<90% (%) 
PCO.01 1.3 1.1-1.6 
P<O.Ol 0.78 o&o.9 
PCO.05 0.88 0.8-0.9 
PCO.05 1.8 1.1-2.9 
PCO.05 1.6 1.1-2.4 
PCO.05 0.3 0.1-0.9 
PCO.05 1.13 1.0-1.26 
PCO.05 1.13 1.0-1.26 
CI, confidence intervals; BMI, body-mass index; PaO,, arterial oxygen tension; PaCO,, arterial 
carbon dioxide tension; SaO,, percentage saturation of haemoglobin with oxygen in arterial blood. 
percentage of time spent at ~90% of SaO,. The odds ratios 
and 95% confidence intervals of the factors of the univariate 
and multivarite analysis are listed in Table 3. 
RESPONSE TO BILEVEL TREATMENT 
Eleven patients were treated with nasal bilevel positive 
airway pressure (BiPAP) in the control mode after the 
initial failure of CPAP. One patient was treated with BiPAP 
in the spontaneous mode because he did not tolerate the 
control mode, and one patient refused further ventilation 
therapy. One-third of the patients complained about initial 
mask problems but in no case was an individual manufac- 
tured mask necessary. The ventilator’s counter revealed a 
mean running time of 5.8 h night - ’ BiPAP ventilation led 
to a significantly (P<O.OOl) lower AH1 (2.6 & 2.3) than 
ventilation with CPAP (14.1 f 7.6). The AH1 of the 
patients treated in the spontaneous mode was 6.5, whereas 
the AH1 of the patients treated in the control mode 
was 15. Mean nocturnal oxygen saturation improved 
significantly (P<O.O05) from 84.6 f 4.5% to 89.6 f 2.9% 
with CPAP and, also significantly (P<O.O5), to 92.1 + 1.4% 
with BiPAP (Fig. 3). Figure 5 gives an example of a 
recording of nocturnal oxygen saturation at baseline, CPAP 
and BiPAP. Minimal nocturnal oxygen saturation 
improved significantly (P<O.O05) from 64.3 * 12.1% to 
74.5 & 10.5% with CPAP and to 83.4 f 5.7% (PcO.01) with 
BiPAP. After 3 months of treatment with BiPAP, awake 
blood gas values improved significantly (PcO.05) from 
7.67 & 1.04 kPa (57.7 f 7.8 mmHg) to 8.51 & 0.97 kPa 
(64 f 7.3 mmHg) for PaO, and from 6.18 f 1.26 kPa 
(46.5 + 9.5 mmHg) to 5.44 f 0.67 kPa (40.9 & 5.0 mmHg) 
for PaCO, (Fig. 4). 
Discussion 
This study found a primary failure of CPAP therapy in 
8.9% in a group of 146 patients with obstructive sleep 
100 
FP< 0.005 --t-P < 0.05 
Baseline CPAP BiPAP 
FIG. 3. Mean nocturnal percentage saturation of 
haemoglobin with oxygen in arterial blood (SaO,) of 
patients who failed to respond to continuous positive 
airway pressure (CPAP) at baseline polysomnography, 
CPAP polysomnography and bilevel positive airway 
pressure (BiPAP) polysomnography. 
, 
apnoea/hypopnoea. These patients were significantly more 
obese and had worse awake blood gas values at rest and at 
exercise than patients treated successfully with CPAP. The 
percentage of time spent at <90% of nocturnal SaO, was 
the only factor which was independently associated with the 
initial failure of CPAP. BiPAP ventilation in the controlled 
mode led to a sufficient treatment of apnoea, hypopnoea 
and hypoventilation. Moreover, awake blood gas values 
improved significantly after a 3-month treatment period. 
Several therapeutic approaches for the management of 
OSA are available. CPAP is generally accepted as the 
treatment of choice and the most widely used therapy. Data 
based on randomized studies about its efficacy in com- 
parison to other treatment modalities such as conservative 
management, surgery or oral appliances demonstrated that 
CPAP is an effective treatment (11,12), but compliance is a 
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FIG. 4. Blood gas values at rest of patients who failed to 
respond to continuous positive airway pressure (CPAP) 
after a 3-month treatment period with bilevel positive 
airway pressure (BiPAP). 
main concern of long-term management (5,13). However, in 
a small group of patients treated with CPAP, prolonged 
hypoventilation persisted despite CPAP, resulting in an 
inadequately high AH1 or a still reduced mean nocturnal 
oxygen saturation (6,7). 
Only limited data on the primary failure of CPAP are 
available. Becker et al. (7) reported their experience with 
CPAP therapy in a large series of patients. They found a 
primary failure of CPAP defined as a persistent AHI of 
2 10 in 5.5% of the whole group of 1140 patients, partly 
because of central apnoea or hypoventilation. The present 
authors defined a primary failure of CPAP as a pesisting 
AHI 25, bearing in mind that even a lower AH1 may be 
associated with persistent symptoms of daytime hyper- 
somnolence. In addition, if mean oxygen saturation was 
<90%, this was defined as failure as well, since ventila- 
tion therapy should ensure an appropriate nocturnal 
oxygenation. 
The aim of this study was to analyse the factors that 
are associated with the initial failure of CPAP, since 
hypoxaemia in the course of hypoventilation may have 
adverse effects in patients at risk (6). To the authors’ 
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knowledge, this is the first study in which these factors have 
been analysed systematically and which includes a control 
group of successfully treated patients for comparison. 
Patients of the control group were obese with a median 
BMI of 31 kg m - 2 but patients of the CPAP-failure group 
were morbidly obese with a median BMI of 44 kg m ~ ‘. 
The impared awake blood gas values with hypercapnia in 
almost half of this group (six of 13 patients) suggests that 
these patients exhibited obesity hypoventilation syndrome 
(OHS), which is characterised by extreme obesity, hyper- 
capnic respiratory failure (14,15) and additionally by OSA 
in most cases (16,17). Factors considered to be critical 
determinants for the development of obesity hypo- 
ventilation are mechanical loading, abnormal chest wall 
mechanics, impaired neuromuscular coupling (l&18), and 
impaired ventilatory control (19) whereas abnormalities in 
respiratory control may be more a consequence than a 
cause of OHS. Pharyngeal obstruction is abolished by 
CPAP, but hypoventilation due to blunted ventilatory 
control persists in these patients. Patients without hyper- 
capnic failure may compensate for the effects of obesity on 
elastic load and respiratory resistance when awake (20), but 
when asleep and in the supine position with additional mass 
loading and reduced functional residual capacity (FRC) 
(21), the balance between ventilatory control and mech- 
anical load is impaired and hypoventilation results despite 
CPAP. In addition, ventilatory muscle fatigue due to an 
obesity-related alteration in thoracic mechanics may pro- 
mote hypoventilation despite CPAP. The PO.UPO.1 max 
ratio as an adequate index for assessing the relative force of 
the inspiratory muscles (10) was impaired in the CPAP- 
failure group, indicating an impaired respiratory muscle 
strength awake. 
The percentage of time spent at ~90% of oxygen 
saturation as the only factor which was independently 
associated with CPAP failure may represent the severity of 
impaired nocturnal ventilation, since all patients were 
matched for AHI. This is in accordance with findings of 
greater oxygen desaturations during sleep in patients with 
OHS than in patients with eucapnic OSA (22). A limitation 
of the present study may be the absence of nocturnal 
capnography and pneumotachography in order to quantify 
exactly the amount of hypoventilation leading to nocturnal 
hypoxemia and hypercapnia. Another limitation of the 
present study may be that ventilatory response measure- 
ments were not performed when patients were awake. 
Nevertheless, PaCO, at exercise changed for the worse in 
the CPAP-failure group, indicating a latent ventilatory 
failure awake, whereas in the control group, it improved 
during exercise. This study excluded patients with flow 
limitation that revealed chronic obstructive pulmonary 
disease as a possible cause of impaired blood gas values. 
Moreover, no statistical association was found between 
FEV, or FEV,/VC ratio and CPAP failure. 
BiPAP in the spontaneous mode had first been applied 
to prevent both complete upper airway obstruction and 
the oxyhaemoglobin desaturations events associated with 
persistent partial obstructions at a mean pressure lower 
than conventional CPAP (23). However, all the patients in 
this study (23) were normocapnic and BiPAP was not 
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FIG. 5. Recording of nocturnal oxygen saturation in one patient resistant to initial continuous positive airway pressure 
(CPAP). Top panel represents baseline polysomnography. The middle panel represents CPAP polysomnography. With the 
exception of the period from hour 1 until 2 (awake), oxygen saturation remains nearly unchanged at 80%. The lower panel 
represents bilevel positive airway pressure (BiPAP) polysomnography. The oxygen saturation remains stable at >QO%. 
superior to CPAP with regard to response. One of the 
present study patients was treated with such a device, 
because he did not tolerate the control mode. AH1 still 
remained at 6.3 and PaCO, was slightly elevated after a 
3-month treatment period in this patient. Nevertheless, it 
is not clear if BiPAP in the controlled mode is superior to 
the spontaneous mode in these patients. Both devices do 
prevent upper airway obstruction sufficiently, but the con- 
trolled mode may adequately prevent hypoventilation and 
therefore normalize chronically blunted central ventilatory 
drive (24). In addition, this mode may improve ventilatory 
muscle strength or endurance (24). Piper and Sullivan 
performed nasal positive pressure ventilation (NIPPV) in 
the controlled mode using a volume-cycled ventilator in 13 
patients with OSA who failed to respond to initial CPAP 
therapy (8). All of these patients were grossly obese and 
hypercapnic. After 7-18 days of NIPPV, nine of the 13 
patients switched back to a regimen of nocturnal CPAP, 
while three patients required a longer period of up to 
3 months before adequate nocturnal ventilation could be 
maintained. One patient required long-term NIPPV. The 
type of ventilator chosen may be potentially more comfort- 
able and may compensate for mild-to-moderate mouth 
leaks, but the issue of CO, rebreathing is not clear (25). 
Further studies are needed to clarify if one device is 
superior to another in this specific group of patients, and 
which patients should or could switch back to a CPAP 
device. 
In conclusion, patients with OSA who resist initial CPAP 
are morbidly obese with impaired awake blood gas values. 
The percentage of time spent at ~90% of SaO, is indepen- 
dently associated, and therefore a predictive factor of 
failure of initial CPAP. BiPAP in the control mode is 
adequate for nocturnal ventilation in these patients 
and improves awake blood gas values after 3 months of 
treatment. 
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